{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T15:02:09Z","timestamp":1794668529812,"version":"4.9.1"},"reference-count":40,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,5,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Stem cell transplant (SCT) outcomes in high-risk and relapsed\/refractory (R\/R) pediatric acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) have been historically poor. Cord blood (CB) allows T-cell replete CB transplant (TRCB), enabling enhanced graft-versus-leukemia. We consecutively collected data from 367 patients undergoing TRCB (112\u00a0patients) or other cell source (255 patients) SCT for pediatric AML\/MDS in the United Kingdom and Ireland between January 2014 and December 2021. Data were collected about the patient\u2019s demographics, disease, and its treatment; including previous transplant, measurable residual disease (MRD) status at transplant, human leukocyte antigen\u2013match, relapse, death, graft versus host disease (GvHD), and transplant-related mortality (TRM). Univariable and multivariable analyses were undertaken. There was a higher incidence of poor prognosis features in the TRCB cohort: 51.4% patients were MRD positive at transplant, 46.4% had refractory disease, and 21.4% had relapsed after a previous SCT, compared with 26.1%, 8.6%, and 5.1%, respectively, in the comparator group. Event free survival was 64.1% within the TRCB cohort, 50% in MRD-positive patients, and 79% in MRD-negative patients. To allow for the imbalance in baseline characteristics, a multivariable analysis was performed where the TRCB cohort had significantly improved event free survival, time to relapse, and reduced chronic GvHD, with some evidence of improved overall survival. The effect appeared similar regardless of the MRD status. CB transplant without serotherapy may be the optimal transplant option for children with myeloid malignancy.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022009253","type":"journal-article","created":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T20:55:05Z","timestamp":1673988905000},"page":"2155-2165","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":47,"title":["T-cell replete cord transplants give superior outcomes in high-risk and relapsed\/refractory pediatric myeloid malignancy"],"prefix":"10.1182","volume":"7","author":[{"given":"Claire","family":"Horgan","sequence":"first","affiliation":[{"name":"1Royal Manchester Children\u2019s Hospital, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khushnuma","family":"Mullanfiroze","sequence":"additional","affiliation":[{"name":"2Great Ormond Street Hospital for Children, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4745-7628","authenticated-orcid":false,"given":"Archana","family":"Rauthan","sequence":"additional","affiliation":[{"name":"2Great Ormond Street Hospital for Children, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine","family":"Patrick","sequence":"additional","affiliation":[{"name":"3Sheffield Children\u2019s NHS Foundation Trust, Sheffield, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naeem Akram","family":"Butt","sequence":"additional","affiliation":[{"name":"4Bristol Royal Hospital for Children, Bristol, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oana","family":"Mirci-Danicar","sequence":"additional","affiliation":[{"name":"4Bristol Royal Hospital for Children, Bristol, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olya","family":"O\u2019Connor","sequence":"additional","affiliation":[{"name":"5The Royal Marsden NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Furness","sequence":"additional","affiliation":[{"name":"5The Royal Marsden NHS Foundation Trust, London, United Kingdom"},{"name":"6The Institute of Cancer Research, Sutton, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay","family":"Deshpande","sequence":"additional","affiliation":[{"name":"7Birmingham Children\u2019s Hospital, Birmingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Lawson","sequence":"additional","affiliation":[{"name":"7Birmingham Children\u2019s Hospital, Birmingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Broderick","sequence":"additional","affiliation":[{"name":"8Children\u2019s Health Ireland at Crumlin, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Evans","sequence":"additional","affiliation":[{"name":"8Children\u2019s Health Ireland at Crumlin, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Gibson","sequence":"additional","affiliation":[{"name":"9Royal Hospital for Children, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wing","family":"Roberts","sequence":"additional","affiliation":[{"name":"10Great North Children\u2019s Hospital, Victoria Wing, Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salah","family":"Ali","sequence":"additional","affiliation":[{"name":"11Leeds Children\u2019s Hospital, Clarendon Wing, Leeds General Infirmary, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sevasti","family":"Galani","sequence":"additional","affiliation":[{"name":"12CR UK & UCL Cancer Trials Centre, UCL Cancer Institute, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy A.","family":"Kirkwood","sequence":"additional","affiliation":[{"name":"12CR UK & UCL Cancer Trials Centre, UCL Cancer Institute, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena","family":"Jovanovic","sequence":"additional","affiliation":[{"name":"13Department of Medical and Molecular Genetics, King\u2019s College London, Strand, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Dillon","sequence":"additional","affiliation":[{"name":"13Department of Medical and Molecular Genetics, King\u2019s College London, Strand, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Virgo","sequence":"additional","affiliation":[{"name":"14Department of Immunology and Immunogenetics, North Bristol NHS Trust, Bristol, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beki","family":"James","sequence":"additional","affiliation":[{"name":"11Leeds Children\u2019s Hospital, Clarendon Wing, Leeds General Infirmary, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanchan","family":"Rao","sequence":"additional","affiliation":[{"name":"2Great Ormond Street Hospital for Children, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0480-3911","authenticated-orcid":false,"given":"Persis J.","family":"Amrolia","sequence":"additional","affiliation":[{"name":"2Great Ormond Street Hospital for Children, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert F.","family":"Wynn","sequence":"additional","affiliation":[{"name":"1Royal Manchester Children\u2019s Hospital, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,5,12]]},"reference":[{"issue":"2","key":"2023052315245885800_bib1","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/s41375-019-0584-8","article-title":"Hematopoietic stem cell transplantation for children with acute myeloid leukemia-results of the AML SCT-BFM 2007 trial","volume":"34","author":"Sauer","year":"2020","journal-title":"Leukemia"},{"issue":"1","key":"2023052315245885800_bib2","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.bbmt.2014.10.026","article-title":"Allogeneic hematopoietic cell transplantation for acute myeloid leukemia","volume":"21","author":"Vyas","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"2023052315245885800_bib3","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Dohner","year":"2022","journal-title":"Blood"},{"issue":"4","key":"2023052315245885800_bib4","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/bjh.13611","article-title":"Outcome of children with acute myeloid leukaemia (AML) experiencing primary induction failure in the AIEOP AML 2002\/01 clinical trial","volume":"171","author":"Quarello","year":"2015","journal-title":"Br J Haematol"},{"issue":"26","key":"2023052315245885800_bib5","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.1200\/JCO.2008.16.4442","article-title":"Unrelated donor bone marrow transplantation for children with acute myeloid leukemia beyond first remission or refractory to chemotherapy","volume":"26","author":"Bunin","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2023052315245885800_bib6","first-page":"48","article-title":"Outcome of refractory and relapsed acute myeloid leukemia in children treated during 2005-2011---experience of the Polish Pediatric Leukemia\/Lymphoma Study Group (PPLLSG)","volume":"18","author":"Skalska-Sadowska","year":"2014","journal-title":"Contemp Oncol (Pozn)"},{"issue":"4","key":"2023052315245885800_bib7","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/bjh.16441","article-title":"Outcome of children relapsing after first allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: a retrospective I-BFM analysis of 333 children","volume":"189","author":"Uden","year":"2020","journal-title":"Br J Haematol"},{"issue":"3","key":"2023052315245885800_bib8","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/pbc.22612","article-title":"Outcome for children treated for relapsed or refractory acute myelogenous leukemia (rAML): a therapeutic advances in childhood leukemia (TACL) consortium study","volume":"55","author":"Gorman","year":"2010","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"2023052315245885800_bib9","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.bbmt.2018.09.016","article-title":"Outcomes after second hematopoietic cell transplantation in children and young adults with relapsed acute leukemia","volume":"25","author":"Lund","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2023052315245885800_bib10","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.bbmt.2014.11.001","article-title":"Strategies for the identification of T cell-recognized tumor antigens in hematological malignancies for improved graft-versus-tumor responses after allogeneic blood and marrow transplantation","volume":"21","author":"Zilberberg","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"2023052315245885800_bib11","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.3389\/fonc.2019.01217","article-title":"The graft-versus-leukemia effect in AML","volume":"9","author":"Sweeney","year":"2019","journal-title":"Front Oncol"},{"issue":"10","key":"2023052315245885800_bib12","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa1602074","article-title":"Cord-blood transplantation in patients with minimal residual disease","volume":"375","author":"Milano","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2023052315245885800_bib13","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1038\/s41375-021-01474-0","article-title":"Comparing cord blood transplantation and matched related donor transplantation in non-remission acute myeloid leukemia","volume":"36","author":"Shimomura","year":"2022","journal-title":"Leukemia"},{"issue":"12","key":"2023052315245885800_bib14","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1038\/bmt.2016.186","article-title":"Chronic graft versus host disease burden and late transplant complications are lower following adult double cord blood versus matched unrelated donor peripheral blood transplantation","volume":"51","author":"Gutman","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"2023052315245885800_bib15","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1182\/bloodadvances.2018025908","article-title":"The influence of stem cell source on transplant outcomes for pediatric patients with acute myeloid leukemia","volume":"3","author":"Keating","year":"2019","journal-title":"Blood Adv"},{"issue":"10","key":"2023052315245885800_bib16","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1182\/bloodadvances.2020001554","article-title":"Adult cord blood transplant results in comparable overall survival and improved GRFS vs matched related transplant","volume":"4","author":"Sharma","year":"2020","journal-title":"Blood Adv"},{"issue":"5","key":"2023052315245885800_bib17","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/j.1365-2141.2011.08994.x","article-title":"Omission of in\u00a0vivo T-cell depletion promotes rapid expansion of naive CD4+ cord blood lymphocytes and restores adaptive immunity within 2\u00a0months after unrelated cord blood transplant","volume":"156","author":"Chiesa","year":"2012","journal-title":"Br J Haematol"},{"issue":"3","key":"2023052315245885800_bib18","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.bbmt.2019.11.001","article-title":"Impact of HLA allele mismatch at HLA-A, -B, -C, and -DRB1 in single cord blood transplantation","volume":"26","author":"Yokoyama","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2023052315245885800_bib19","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.bbmt.2013.10.016","article-title":"Impact on outcomes of human leukocyte antigen matching by allele-level typing in adults with acute myeloid leukemia undergoing umbilical cord blood transplantation","volume":"20","author":"Sanz","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2023052315245885800_bib20","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMsa1311707","article-title":"HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry","volume":"371","author":"Gragert","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"2023052315245885800_bib21","doi-asserted-by":"crossref","first-page":"6064","DOI":"10.1182\/bloodadvances.2020003371","article-title":"High progression-free survival after intermediate intensity double unit cord blood transplantation in adults","volume":"4","author":"Barker","year":"2020","journal-title":"Blood Adv"},{"issue":"26","key":"2023052315245885800_bib22","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1182\/blood-2015-06-654780","article-title":"Cord blood T cells mediate enhanced antitumor effects compared with adult peripheral blood T cells","volume":"126","author":"Hiwarkar","year":"2015","journal-title":"Blood"},{"issue":"4","key":"2023052315245885800_bib23","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00007890-197410000-00001","article-title":"Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors","volume":"18","author":"Glucksberg","year":"1974","journal-title":"Transplantation"},{"issue":"3","key":"2023052315245885800_bib24","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"2023052315245885800_bib25","doi-asserted-by":"crossref","first-page":"659595","DOI":"10.3389\/fimmu.2021.659595","article-title":"Allogeneic stem cell transplantation for acute myeloid leukemia: who, when, and how?","volume":"12","author":"Loke","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"2023052315245885800_bib26","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/bjh.16355","article-title":"The role of allogeneic stem cell transplantation in the management of acute myeloid leukaemia: a triumph of hope and experience","volume":"188","author":"Loke","year":"2020","journal-title":"Br J Haematol"},{"key":"2023052315245885800_bib27","volume-title":"Myechild 01 International Randomised Phase III Clinical Trial in Children with Acute Myeloid Leukaemia","year":"2018"},{"issue":"7","key":"2023052315245885800_bib28","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1200\/JCO.20.02308","article-title":"Augmented reduced-intensity regimen does not improve postallogeneic transplant outcomes in acute myeloid leukemia","volume":"39","author":"Craddock","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"9577","key":"2023052315245885800_bib29","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1016\/S0140-6736(07)60915-5","article-title":"Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study","volume":"369","author":"Eapen","year":"2007","journal-title":"Lancet"},{"issue":"7","key":"2023052315245885800_bib30","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1038\/s41409-021-01227-8","article-title":"Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years","volume":"56","author":"Passweg","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"2023052315245885800_bib31","doi-asserted-by":"crossref","first-page":"836594","DOI":"10.3389\/fcell.2022.836594","article-title":"Strategies for success with umbilical cord haematopoietic stem cell transplantation in children with malignant and non-malignant disease indications","volume":"10","author":"Wynn","year":"2022","journal-title":"Front Cell Dev Biol"},{"issue":"25","key":"2023052315245885800_bib32","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"17","key":"2023052315245885800_bib33","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1200\/JCO.20.01086","article-title":"Phase II trial of costimulation blockade with abatacept for prevention of acute GVHD","volume":"39","author":"Watkins","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"2023052315245885800_bib34","doi-asserted-by":"crossref","first-page":"e134","DOI":"10.1016\/S2352-3026(19)30202-9","article-title":"Hematopoietic stem cell transplantation using single UM171-expanded cord blood: a single-arm, phase 1-2 safety and feasibility study","volume":"7","author":"Cohen","year":"2020","journal-title":"Lancet Haematol"},{"issue":"16","key":"2023052315245885800_bib35","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1182\/blood.2021011719","article-title":"Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study","volume":"138","author":"Horwitz","year":"2021","journal-title":"Blood"},{"issue":"3","key":"2023052315245885800_bib36","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/bjh.13136","article-title":"Results of a prospective multicentre myeloablative double-unit cord blood transplantation trial in adult patients with acute leukaemia and myelodysplasia","volume":"168","author":"Barker","year":"2015","journal-title":"Br J Haematol"},{"issue":"4","key":"2023052315245885800_bib37","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.bbmt.2014.12.023","article-title":"Comparison of conditioning regimens with or without antithymocyte globulin for unrelated cord blood transplantation in children with high-risk or advanced hematological malignancies","volume":"21","author":"Zheng","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2023052315245885800_bib38","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s13045-018-0655-8","article-title":"Haploidentical transplantation is associated with better overall survival when compared to single cord blood transplantation: an EBMT-Eurocord study of acute leukemia patients conditioned with thiotepa, busulfan, and fludarabine","volume":"11","author":"Giannotti","year":"2018","journal-title":"J\u00a0Hematol Oncol"},{"issue":"26","key":"2023052315245885800_bib39","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1182\/blood-2016-01-694349","article-title":"Single- vs double-unit cord blood transplantation for children and young adults with acute leukemia or myelodysplastic syndrome","volume":"127","author":"Michel","year":"2016","journal-title":"Blood"},{"issue":"1","key":"2023052315245885800_bib40","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1182\/blood-2013-05-506253","article-title":"Impact of allele-level HLA matching on outcomes after myeloablative single unit umbilical cord blood transplantation for hematologic malignancy","volume":"123","author":"Eapen","year":"2014","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/10\/2155\/2052482\/blooda_adv-2022-009253-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/10\/2155\/2052482\/blooda_adv-2022-009253-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T15:46:34Z","timestamp":1684856794000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/10\/2155\/494141\/T-cell-replete-cord-transplants-give-superior"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,12]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,5,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022009253","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,12]]}}}